The clinical implications of impaired glucose tolerance

Diabetic Medicine

Volumn 13, Issue 11, 1996, Pages 927-937

  Alberti, K G M M ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Blood glucose; Cardiovascular disease; Impaired glucose tolerance; Mortality; Non insulin dependent diabetes mellitus; Risk factors

Indexed keywords

ACARBOSE; GLIBENCLAMIDE; GLICLAZIDE; GLUCOSE; METFORMIN; PHENFORMIN; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE; TROGLITAZONE;

CARDIOVASCULAR DISEASE; GLUCOSE TOLERANCE; HUMAN; INSULIN RESISTANCE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK FACTOR;

ADULT; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; EMBRYONIC AND FETAL DEVELOPMENT; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; NUTRITION DISORDERS; PREGNANCY; PREVALENCE; RISK FACTORS;

EID: 0029828082     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9136(199611)13:11<927::AID-DIA279>3.0.CO;2-E     Document Type: Review

References (124)

1. West KM. Epidemiology of Diabetes and its Vascular Complications. New York: Elsevier, 1978.
2. Keen H, Jarrett RJ, Alberti KGMM. Diabetes mellitus: a new look at diagnostic criteria. Diabetologia 1979; 16: 283-285.
3. WHO Expert Committee. Diabetes Mellitus, 2nd Report. WHO Technical Report Series 646. Geneva: WHO, 1980.
4. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1038-1057.
5. Jarrett RJ, Keen H. Hyperglycaemia and diabetes mellitus. Lancet 1976; ii: 1009-1012.
6. Jarrett RJ, Al Sayegh H. Impaired glucose tolerance: defining those at risk of diabetic complications. Diabetologia 1978; 15: 243.
7. Bennett PH, Rushforth NB, Miller M, Le Compte P. Epidemiological studies in diabetes in the Pima Indians. Recent Prog Horm Res 1976; 32: 333-376.
8. Alberti KGMM, Burrin JM. What is blood glucose: can it be measured? Diabetic Med 1990; 7: 199-206.
9. WHO Study Group on Diabetes. WHO Technical Report Series 727. Geneva: WHO, 1985.
10. Finch CF, Zimmet PZ, Alberti KGMM. Determining diabetes prevalence: a rational basis for the use of fasting plasma glucose concentrations. Diabetic Med 1990; 7: 603-610.
11. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH. The natural history of impaired glucose tolerance in the Pima Indians. New Engl J Med 1988; 319: 1500-1506.
12. McDonald CW, Fisher GF, Burnham C. Reproducibility of the oral glucose tolerance test. Diabetes 1965; 14: 473-480.
13. Swai ABM, McLarty DG, Kitange HM, Kilima PM, Masuki C, Mtinangi BI, et al. Study in Tanzania of impaired glucose tolerance - methodological myth? Diabetes 1991; 40: 516-520.
14. Riccardi C, Vaccaro O, Rivellese A, Pignalosa S, Tutino L, Mancini M. Reproducibility of the new diagnostic criteria for impaired glucose tolerance. Am J Epidemiol 1985; 121: 422-429.
15. Glatthaar C, Welborn TA, Stenhouse NS, Garcia-Webb P. Diabetes and impaired glucose tolerance: a prevalence estimate based on the Busselton 1981 survey. Med J Aust 1985; 143: 436-440.
16. Forrest RD, Jackson DA, Yudkin JS. The abbreviated glucose tolerance test in screening for diabetes. Diabetic Med 1988; 5: 557-561.
17. Yudkin JS, Forrest RD, Jackson CA. Misclassification of diabetic subjects may account for the increased vascular risk of impaired glucose tolerance: the Islington Diabetes Survey. Diab Res Clin Pract 1991; 13: 1-14.
18. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Bennett PH. Transient impaired glucose tolerance in Pima Indians: Is it important? Br Med J 1988; 297: 1438-1441.
19. Swai ABM, Harrison K, Chuwa LM, Makene W, McLarty D, Alberti KGMM. Screening for diabetes: does measurement of fructosamine help? Daibetic Med 1988; 5: 648-652.
20. Albutt EC, Nattrass M, Northam BE. Glucose tolerance test and glycosylated haemoglobin measurement for diagnosis of diabetes mellitus - an assessment of the criteria of the WHO Expert Committee. Ann Clin Biochem 1985; 22: 67-73.
21. Page RCL, Harnden KE, Walravens NKN, Onslow C, Sutton P, Levy JC et al. 'Healthy living' and sulphonylurea therapy have different effects on glucose tolerance and risk of cardiovascular disease in subjects with impaired glucose tolerance. Q J Med 1993; 86: 145-154.
22. De Fronzo RA, Bonadonna RC, Ferannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992; 14: 968-974.
23. Reaven GM, Hollenbeck CB, Chen Y-DI. Relationship between glucose tolerance, insulin secretion, and insulin action in non-obese individuals with varying degrees of glucose intolerance. Diabetologia 1989; 32: 52-55.
24. Byrne MM, Sturis J, Sobel RJ, Polonsky KS. Elevated plasma glucose 2-h postchallenge predicts defects in β-cell function. Am J Physiol 1996; 270: E572-E579.
25. Lillioja S, Mott DM, Howard BV, Bennett PH, Yki-Jarvinen H, Freymond D et al. Impaired glucose tolerance as a disorder of insulin action: longitudinal and cross-sectional studies in Pima Indians. New Engl J Med 1988; 318: 1217-1225.
26. Walker M, Berrish TS, Stewart MW, Humphriss DB, Barriocanal L. Metabolic heterogeneity in impaired glucose tolerance. Diabetologia 1995; 38 (suppl 1): A11.
27. Swinburn BA, Gianchandani R, Saad MF, Lillioja S. In vivo β-cell function at the transition to early non-insulin-dependent diabetes mellitus. Metabolism 1995; 44: 757-764.
28. Davies MJ, Rayman G, Grenfell A, Gray IP, Day JL, Hales CN. Loss of the first phase insulin responses to intravenous glucose in subjects with impaired glucose tolerance. Diabetic Med 1994; 11: 432-436.
29. Berrish TS, Hetherington CS, Alberti KGMM, Walker M. Peripheral and hepatic insulin sensitivity in subjects with impaired glucose tolerance. Diabetologia 1995; 38: 699-704.
30. Davies MJ, Rayman G, Gray IP, Day JL, Hales CN. Insulin deficiency and increased plasma concentration of intact and 32/33 split proinsulin in subjects with impaired glucose tolerance. Diabetic Med 1993; 10: 313-320.
31. Birkeland KI, Torjesen PA, Eriksson J, Vaaler S, Group L. Hyperproinsulinaemia of Type II diabetes is not present before the development of hyperglycemia. Diabetes Care 1994; 17: 1307-1310.
32. Krentz AJ, Singh BM, Nattrass M. Impaired glucose tolerance is characterized by multiple abnormalities in the regulation of intermediary metabolism. Diabetic Med 1991; 8: 848-854.
33. Hughes VA, Fiatarone MA, Fielding RA, Kahn BB, Ferrara CM, Shepherd P et al. Exercise increases muscle GLUT-4 levels and insulin action in subjects with impaired glucose tolerance. Am J Physiol 1993; 264: E855-E862.
34. Ohmura T, Ueda K, Kiyohara Y, Kato I, Iwamoto H, Nakayama K, et al. Prevalence of Type 2 (non-insulin dependent) diabetes mellitus and impaired glucose tolerance in the Japanese general population: the Hisayama study. Diabetologia 1993; 36: 1198-1203.
35. Zimmet P, Taylor RR, Whitehouse S. Prevalence rates of impaired glucose tolerance and diabetes mellitus in various Pacific populations according to the new WHO criteria. WHO Bull 1982; 60: 279-282.
36. Swai ABM, McLarty D, Sherrif F, Chuwa LM, Maro E, Lukmanji Z et al. Diabetes and impaired glucose tolerance in an Asian community in Tanzania. Diab Res Clin Pract 1990; 8: 227-234.
37. Dowse GK, Gareeboo H, Zimmet P, Alberti KGMM, Tuomilehto J, Fareed D et al. The high prevalence of non-insulin dependent diabetes and impaired glucose tolerance in Indian, Creole and Chinese Mauritians. Diabetes 1990; 39: 390-396.
38. Briceno I, Barriocanal LA, Papiha SS, Ashworth LA, Gomez A, Bernai JE, et al. Lack of diabetes in rural Colombian Amerindians. Diabetes Care 1996: 19: 900-901.
39. Zimmet P, Taylor R, Ram P, King H, Sloman G, Raper LR, Hunt D. Prevalence of diabetes and impaired glucose tolerance in the biracial (Melanesian and Indian) population of Fiji: a rural urban comparison. Am J Epidemiol 1983; 118: 673-688.
40. McLarty DG, Swai ABM, Kitange HM, et al. Prevalence of diabetes and impaired glucose tolerance in rural Tanzania. Lancet 1989; i: 871-875.
41. Harris MI, Hadden WC, Knowler WC, Bennett PH. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in US population aged 20-74 yrs. Diabetes 1987; 36: 523-534.
42. Tuomilehto J, Korhonen HJ, Kartovaara L, Salomaa V, Stengard JH, Pitkanen M et al. Prevalence of diabetes mellitus and impaired glucose tolerance in the middle-aged population of three areas in Finland, Int J Epidemiol 1991; 20: 1010-1017.
43. Stengard JH, Tuomilehto J, Pekkanen J, Kivinen P, Kaarsalo E, Nissinen A, Karvonen MJ. Diabetes mellitus, impaired glucose tolerance and mortality among elderly men: the Finnish cohorts of the Seven Countries Study. Diabetologia 1992; 35: 760-765.
44. Unwin N, Harland J, White M, Bhopal R, Winocour P, Stephenson P et al. Body mass index, waist-hip ratio and glucose intolerance in Chinese and Europid adults. J Epidemiol Comm Hlth 1997; in press.
45. Mooy JM, Grootenhuis PA, De Vries H, Valkenberg HA, Bouter LM, Kostense PJ, Heine RJ. Prevalence and determinants of glucose intolerance in a Dutch Caucasian population. Diabetes Care 1995; 18: 1270-1273.
46. Shera AS, Rafique C, Khwaja IA, Ara J, Baqai S, King H. Pakistan National Diabetes Survey: prevalence of glucose tolerance and associated factors in Shikapur, Sindh province. Diabetic Med 1995; 12: 1116-1121.
47. Asfour MG, Lambourne A, Soliman A, Al-Behlani S, Al-Asfoor D, Bold A, Mahtab H, King H. High prevalence of diabetes mellitus and impaired glucose tolerance in the Sultanate of Oman: results of the 1991 national survey. Diabetic Med 1995; 12: 1122-1125.
48. Herman WH, Ali MA, Aubert RE, Engelgau MM Kenny SJ, Gunter EW, et al. Diabetes mellitus in Egypt: risk factors and prevalence. Diabetic Med 1995; 12: 1126-1131.
49. Brown DC, Byrne CD, Clark PMS, Cox L, Day NE, Hales CN, et al. Height and glucose tolerance in adult subjects. Diabetologia 1991; 34: 531-533.
50. Dowse GK, Spark RA, Mavo B, Hodge AM, Erasmus RT, Gwalimu M, et al. Extraordinary prevalence of non-insulin dependent diabetes mellitus and bimodal plasma glucose distribution in the Wanigela people of Papua New Guinea. Med J Aust 1994; 160: 767-774.
51. King H, Rewers M, WHO Ad Hoc Reporting Group. Global estimates for the prevalence of diabetes mellitus and impaired glucose tolerance in adults. Diabetes Care 1993; 16: 157-177.
52. Harris MI. Impaired glucose tolerance in the US population. Diabetes Care 1989; 12: 464-474.
53. Schranz A, Tuomilehto J, Marti B, Jarrett RJ, Grabauskas V, Vassallo A. Low physical activity and worsening of glucose intolerance: results from a two-year follow-up of a population sample in Malta. Diab Res Clin Pract 1991; 11: 127-136.
54. Annuzzi G, Vaccaro O, Caprio S, Di Bonito P, Caso P, Riccardi G, et al. Association between habitual physical activity and impaired glucose tolerance. Clin Physiol 1985; 5: 63-70.
55. Lindgarde F, Saltin B. Daily physical activity, work capacity and glucose tolerance in lean and obese normoglycaemic middle-aged men. Diabetologia 1981; 20: 134-138.
56. Modan M, Karasik A, Halkin H, Fuchs Z, Lusky A, Shitrit A, et al. Effect of past and concurrent body mass index on prevalence of glucose intolerance and Type 2 (non-insulin dependent) diabetes and on insulin response. Diabetologia 1986; 29: 82-89.
57. Knowler WC, Pettitt DJ, Savage PJ, Bennett PH. Diabetes incidence in Pima Indians: contributions of obesity and parental diabetes. Am J Epidemiol 1981; 113: 144-156.
58. O'Dea K, Traiznedes K, Hopper JL, Larkins RG. Impaired glucose tolerance, hyperinsulinemia and hypertriglyceridemia in Australian Aborigines from the desert. Diabetes Care 1988; 11: 23-29.
59. Zavaroni I, Mazza S, Luchetti L, Buonanwo G, Bonati PA, Bergonzani M, et al. High plasma insulin and triglyceride concentrations and blood pressure in off-spring of people with impaired glucose tolerance. Diabetic Med 1990; 7: 494-498.
60. Hales CN, Barker DJP, Clark PMS, Cox LJ, Fall C, Osmond C, Winter PD. Fetal and infant growth and impaired glucose tolerance at age 64. Br Med J 1991; 303: 1019-1022.
61. Phipps K, Barker JDP, Hales CN, Fall CHD, Osmond C, Clark PMS. Fetal growth and impaired glucose tolerance in men and women. Diabetologia 1993; 36: 225-228.
62. Umeki S, Hisamoto N, Hara Y. Study on background factors associated with impaired glucose tolerance and/or diabetes mellitus. Acta Endocrinol 1989; 120: 729-734.
63. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
64. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963; 1: 785-789.
65. Yudkin JS, Alberti KGMM, McLarty DG, Swai ABM. Impaired glucose tolerance. Is it a risk factor for diabetes or a diagnostic ragbag? Br Med J 1990; 301: 397-402.
66. Jarrett RJ, Keen H, Fuller JH, McCartney P. Worsening to diabetes in men with impaired glucose tolerance ('borderline diabetes'). Diabetologia 1979; 16: 25-30.
67. Keen H, Jarrett RJ, McCartney P. The ten-year follow-up of the Bedford Study (1962-72): Glucose tolerance and diabetes. Diabetologia 1982; 22: 73-78.
68. King H, Zimmet P, Raper LR, Balkau B. The natural history of impaired glucose tolerance in the Micronesian population of Naura: a six-year follow-up study. Diabetologia 1984; 26: 39-48.
69. Ramachandran A, Snehalatha C, Naik RAS, Mohan V, Shobana R, Visvanathan M. Significance of impaired glucose tolerance in an Asian Indian population: a follow-up study. Diab Res Clin Pract 1986; 2: 173-178.
70. Motala AA, Omar MAK, Gouws E. High risk of progression to NIDDM in South African Indians with impaired glucose tolerance. Diabetes 1993; 42: 556-563.
71. Schranz AG. Abnormal glucose tolerance in the Maltese. A population-based longitudinal study of the natural history of NIDDM and IGT in Malta. Diab Res Clin Pract 1989; 7: 7-16.
72. Swai ABM, McLarty DG, Chuwa LM, et al. Diabetes and impaired glucose tolerance in an Asian community in Tanzania. Diab Res Clin Pract 1990; 8: 227-234.
73. Agner E, Thorsteinsson B, Eriksen M. Impaired glucose tolerance and diabetes mellitus in elderly subjects. Diabetes Care 1982; 5: 600-604.
74. Stengard JH, Pekkanen J, Tuomilehto J, Kivinen P, Kaar Salo E, Tamminen M, et al. Changes in glucose tolerance among elderly Finnish men during a five-year follow-up: the Finnish cohorts of the Seven Countries Study. Diabete Metab 1993; 19: 121-129.
75. Tukvitonga CF. Progress of impaired glucose tolerance to diabetes mellitus among Niueans. N Z Med J 1990; 103: 351-353.
76. Heine RJ, Nijpels J, Mooy JM. New data on the rate of progression of impaired glucose tolerance to NIDDM and predicting factors. Diabetic Med 1996; 13 (suppl 2): S12-S14.
77. Sartor C, Schersten B, Carlström S, Melander A, Norden A, Persson G. Ten-year follow-up of subjects with impaired glucose tolerance. Prevention of diabetes by tolbutamide and diet regulation. Diabetes 1980; 29: 41-49.
78. Jarrett RJ, Keen H, McCartney P. The Whitehall Study: ten year follow-up report on men with impaired glucose tolerance with reference to worsening to diabetes and predictors of death. Diabetic Med 1984; 1: 279-283.
79. Sasaki A, Suzuki T, Horiuchi N. Development of diabetes in Japanese subjects with impaired glucose tolerance: a seven-year follow-up study. Diabetologia 1982; 22: 154-157.
80. Kadowaki T, Miyake Y, Hagura R, Akanuma Y, Kajinuma H, Kuzuya N, et al. Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. Diabetologia 1984; 26: 44-49.
81. Cook JTE, Page RCL, Levy JC, Hammersley MS, Walravens EKN, Turner RC. Hyperglycaemic progression in subjects with impaired glucose tolerance: association with decline in beta cell function. Diabetic Med 1993; 10: 321-326.
82. Sicree RA, Zimmet PZ, King HOM, Coventry JS. Plasma insulin response among Nauruans, prediction of deterioration in glucose tolerance over six years. Diabetes 1987; 36: 179-186.
83. Charles MA, Fontbonne A, Thibult N, Warnet JM, Rosselin CE, Eshwege E. Risk factors for NIDDM in a white population. Paris prospective study. Diabetes 1991; 40: 796-799.
84. Inoue J, Takahashi K, Katayama S, Harada Y, Negishi K, Ishii J, et al. A higher proinsulin response to glucose loading predicts deteriorating fasting plasma glucose and worsening to diabetes in subjects with impaired glucose tolerance. Diabetic Med 1996; 13: 330-336.
85. Everhart JE, Pettitt DJ, Bennett PH, Knowler WC. Duration of obesity increases the incidence of NIDDM. Diabetes 1992; 41: 235-240.
86. Harris MI. Impaired glucose tolerance: prevalence and progression to NIDDM. IDF Bulletin 1996; 41: 12-15.
87. Stamler R, Stamler J, eds. Asymptomatic hyperglycaemia and coronary heart disease: a series of papers by the international collaborative group based upon studies in fifteen populations. J Chron Dis 1979; 32: 683-837.
88. Fuller JH, Shipley MJ, Rose C, Jarrett RJ, Keen H. Coronary heart disease risk and impaired glucose tolerance. The Whitehall Study. Lancet 1980; i: 1373-1376.
89. Eschwege E, Richard JL, Thibult N, Ducimetiere P, Warnet JM, Claude JR, et al. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels: the Paris Prospective Study, ten years later. Horm Metab Res 1985; 17 (suppl 15): 41-46.
90. Pan W-H, Cedres LB, Liu K, Dyer A, Schoenberger JA, Shekelle RB, et al. Relationship of clinical diabetes and symptomatic hyperglycemia to risk of coronary heart disease mortality in men and women. Am J Epidemiol 1986; 123: 504-516.
91. Perry IJ, Wannamethee C, Whincup PH, Shaper AG. Asymptomatic hyperglycemia and major ischaemic heart disease events in Britain. J Epidemiol Comm Health 1994; 48: 538-542.
92. Yarnell JWG, Pickering JE, Elwood PC, Baker IA, Bainton D, Dawkins C, et al. Does non-diabetic hyperglycaemia predict future IHD? Evidence from the Caerphilly and Speedwell studies. J Clin Epidemiol 1994; 47: 383-388.
93. Fontbonne A, Eschwege E, Cambien F, Richard J-L, Ducimetiere P, Thibult N, et al. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes: results from the 11-year fol low-up of the Paris Prospective Study. Diabetologia 1989; 32: 300-304.
94. Ohlson L-O, Bjuro T, Larsson B, Eriksson H, Svardsudd K, Welin L, Wilhelmsen L. A cross-sectional analysis of glucose tolerance and cardiovascular disease in 67-year-old men. Diabetic Med 1989; 6: 112-120.
95. Rewers M, Shetterly SM, Baxter J, Marshall JA, Hamman RF. Prevalence of coronary heart disease in subjects with normal and impaired glucose tolerance and non-insulin-dependent diabetes mellitus in a biethnic Colorado population: the San Luis Valley Study. Am J Epidemiol 1992; 135: 1321-1330.
96. Pan X-R, Liu P-A, Hu Y-H, Bennett PH, Li G-W, Howard BV. Impaired glucose tolerance and its relationship to ECG-indicated coronary heart disease and risk factors among Chinese: Da Qing IGT and diabetes study. Diabetes Care 1993; 16: 150-156.
97. McPhillips JB, Barrett-Connor E, Wingard DL. Cardiovascular disease risk factors prior to the diagnosis of impaired glucose tolerance and non-insulin-dependent diabetes mellitus in a community of older adults. Am J Epidemiol 1990; 131: 443-453.
98. Laws A, Marcus EB, Grove JS, Curb JD. Lipids and lipoproteins as risk factors for coronary heart disease in men with abnormal glucose tolerance: the Honolulu Heart Program. J Intern Med 1993; 234: 471-478.
99. Jarrett RJ. Type 2 (non-insulin-dependent) diabetes mellitus and coronary heart disease - chicken, egg or neither? Diabetologia 1984; 26: 99-102.
100. Jarrett RJ. The cardiovascular risk associated with impaired glucose tolerance. Diabetic Med 1996; 13: S15-S19.
101. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes. J Am Med Assoc 1990; 263: 2893-2898.
102. Vaccaro O, Rivellese A, Riccardi G, Capaldo B, Tutino L, Annuzzi G, Mancini M. Impaired glucose tolerance and risk factors for atherosclerosis. Atherosclerosis 1984; 4: 592-597.
103. Yamada N, Gotoda T, Yoshinaga H, Ohashi Y, Sakurai N, Yazaki Y, et al. Increased risk factors for coronary heart disease in Japanese subjects with hyperinsulinaemia of glucose intolerance. Diabetes Care 1994; 17:107-114.
104. Fujimoto WY, Bergstrom RW, Leonetti DL, Newell-Morris LL, Shuman WP, Wahl PW. Metabolic and adipose risk factors for NIDDM and coronary disease in third-generation Japanese-American men and women with impaired glucose tolerance. Diabetologia 1994; 37: 524-532.
105. Melander A. Intervention trials in impaired glucose tolerance. IDF Bulletin 1996; 41: 22-24.
106. Fajans SS, Conn JW. Tolbutamide-induced improvement in carbohydrate tolerance of young people with mild diabetes mellitus. Diabetes 1960; 9: 83-88.
107. Engelhardt HT, Vecchio TJ. The long-term effect of tolbutamide on glucose tolerance in adults, asymptomatic, latent diabetes. Metabolism 1965; 14: 885-890.
108. Belknap BH, Bagdade JD, Amaral JAP, Bierman EL. Plasma lipids and mild glucose intolerance. A double blind study of the effect of tolbutamide and placebo in mild adult diabetic outpatients. Excerpta Med Intl Congr Ser 1967; 149: 171-176.
109. Paasikiva J. Long term tolbutamide treatment after myocardial infarction. Acta Med Scand 1970; suppl 507.
110. Camerini-Davalos RA. Treatment of 'chemical' diabetes. Excerpta Medica Intl Congr Ser 1967; 149: 228-242.
111. Papoz L, Job D, Eschwege E, Aboulker JP, Cubeau J, Pequignot G, et al. Effect of oral hypoglycaemic drugs on glucose tolerance and insulin secretion in borderline diabetic patients. Diabetologia 1978; 15: 373-380.
112. Ratzman KP, Witt S, Schulz B. The effect of long-term glibenclamide treatment on glucose tolerance, insulin secretion and serum lipids in subjects with impaired glucose tolerance. Diab Metab 1983; 9: 87-93.
113. Cederholm J. Short-term treatment of glucose intolerance in middle-aged subjects by diet, exercise and sulfonylurea. Upsala J Med Sci 1985; 90: 229-242.
114. Karunakaran S, Hammersley MS, Morris RJ, Holman RR for the Fasting Hyperglycaemia Study Group. Randomised controlled trial of sulphonylurea therapy in 227 subjects with persistent fasting hyperglycaemia. Diabetes 1995; 44 (suppl 1): 160A.
115. Jarrett RJ, Keen H, Fuller JH, McCartney M. Treatment of borderline diabetes: controlled trial using carbohydrate restriction and phenformin. Br Med J 1977; 2: 861-865.
116. Akinmokun A, Harris P, Home PD, Alberti KGMM. Is diabetes always diabetes? Diabetes Res Clin Pract 1992; 18: 131-136.
117. Eriksson K-F, Lindgarde F. Prevention of Type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The six-year Malmö feasibility study. Diabetologia 1991; 34: 891-898.
118. Page RCL, Harnden KE, Cook JTE, Turner RC. Can lifestyles of subjects with impaired glucose tolerance be changed? A feasibility study. Diabetic Med 1992; 9: 562-566.
119. Ramaiya KL, Swai ABM, Alberti KGMM, McLarty D. Lifestyle changes decrease rates of glucose intolerance and cardiovascular (CVD) risk factors: a six-year intervention study in a high risk Hindu Indian sub-community. Diabetologia 1992; 35 (suppl 1): A60.
120. Bourn DM, Mann JI, McSkimming BJ, Waldron MA, Wishart JD. Impaired glucose tolerance and NIDDM: Does a lifestyle intervention program have an effect? Diab Care 1994; 17: 1311-1319.
121. Dyson PA, Hammersley MS, Karunakaran S, Morris RJ, Turner RC for the Fasting Hyperglycaemia Study Group. Intensive healthy living advice improved physical fitness and reduced self-reported fat intake but had no effect on glycaemia in subjects with persistent fasting glycaemia (Abstract). Diabetes 1995; 44 (suppl 1): 70A.
122. Chiasson JL. Possible therapeutic approaches to impaired glucose tolerance. IDF Bulletin 1996; 41: 16-20.
123. Chiasson J-L, Josse RG, Letier LA, Mihic M, Nathan DM, Palmason C, Wolever TMS. Can we prevent the development of non-insulin-dependent diabetes mellitus (Abstract)? Diabetes 1994; 43 (suppl 1): 62A.
124. Nolan JJ, Ludvik B, Beerdsen P, Joyce P, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994; 231: 1188-1193.